Related references
Note: Only part of the references are listed.Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis
Paolo Strati et al.
ANNALS OF HEMATOLOGY (2019)
Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy
Yasutaka Fukuda et al.
HAEMATOLOGICA (2019)
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale
Michele Provenzano et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Sergio Ferreira Cristina et al.
SEMINARS IN HEMATOLOGY (2018)
Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study
Seung-Woo Baek et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2018)
Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review
Roy O. Mathew et al.
KIDNEY INTERNATIONAL (2017)
Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients
Mahnur Haider et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward
Adeera Levin et al.
KIDNEY INTERNATIONAL (2014)
Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms
Alexander Sidelmann Christensen et al.
LEUKEMIA RESEARCH (2014)
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hans Carl Hasselbalch
BLOOD (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD
Kidney International Supplements (2012)
Myeloproliferative neoplasms cause glomerulopathy
Samar M. Said et al.
KIDNEY INTERNATIONAL (2011)
LACTIC DEHYDROGENASE IN KIDNEY TISSUE AND RENAL DISEASE
Viggo Kamp Nielsen et al.
ACTA MEDICA SCANDINAVICA (2010)
Atherosclerosis in CKD: differences from the general population
Tilman B. Drueeke et al.
NATURE REVIEWS NEPHROLOGY (2010)
Chronic kidney disease and venous thromboembolism: a prospective study
Aaron R. Folsom et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Chronic kidney disease increases risk for venous thromboembolism
Keattiyoat Wattanakit et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Kidney disease as a risk factor for development of cardiovascular disease - A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention
MJ Sarnak et al.
HYPERTENSION (2003)
Share Paper
